<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 12 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.apple-converted-space
{mso-style-name:apple-converted-space;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:2111856455;
mso-list-template-ids:-293281594;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.75in;
mso-level-number-position:left;
margin-left:.75in;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="blue" vlink="purple">
<div class="WordSection1">
<p class="MsoNormal">Hi All,<o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal">Just FYI: yesterday, the House-Senate Opioid Conferees held a
<a href="https://energycommerce.house.gov/hearings-and-votes/event/meeting-house-and-senate-conferees-s-524">
meeting</a> to consider legislative text for S. 524, the “Comprehensive Addiction and Recovery Act of 2016’’ (CARA bill).
<o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal">The current <a href="http://docs.house.gov/meetings/IF/IF00/20160706/105173/BILLS-114S524rth.pdf">
CARA legislation draft</a> includes a very short/vague piece on <b>take-back</b>, with
<b>no mention of EPR</b> (Pg. 58-59): <o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">8 <b>SEC. 203. PRESCRIPTION DRUG TAKE BACK EXPANSION</b>.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">9 (a) DEFINITION OF COVERED ENTITY.—In this sec-
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">10 tion, the term ‘‘covered entity’’ means—
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">11 (1) a State, local, or tribal law enforcement
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">12 agency;
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">13 (2) a manufacturer, distributor, or reverse dis-
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">14 tributor of prescription medications;
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">15 (3) a retail pharmacy;
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">16 (4) a registered narcotic treatment program;
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">17 (5) a hospital or clinic with an onsite pharmacy;
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">18 (6) an eligible long-term care facility; or
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">19 (7) any other entity authorized by the Drug
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">20 Enforcement Administration to dispose of prescrip-
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">21 tion medications.
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D">22 (b) PROGRAM AUTHORIZED.—<b>The Attorney General,
<o:p></o:p></b></span></p>
<p class="MsoNormal" style="margin-left:.5in"><b><span style="color:#1F497D">23 in coordination with the Administrator of the Drug En-
<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-left:.5in"><b><span style="color:#1F497D">24 forcement Administration, the Secretary of Health and
<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-left:.5in"><b><span style="color:#1F497D">25 Human Services, and the Director of the Office of Na-</span></b><span style="color:#1F497D">
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-left:.5in"><b><span style="color:#1F497D">1 tional Drug Control Policy, shall coordinate with covered
<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-left:.5in"><b><span style="color:#1F497D">2 entities in expanding or making available disposal sites for
<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-left:.5in"><b><span style="color:#1F497D">3 unwanted prescription medications.<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-left:.5in"><span style="color:#1F497D"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-left:.75in;text-indent:-.25in;mso-list:l0 level1 lfo1;background:white">
<![if !supportLists]><span style="font-size:10.0pt;font-family:Symbol;color:#333333"><span style="mso-list:Ignore">·<span style="font:7.0pt "Times New Roman"">
</span></span></span><![endif]><span style="color:#333333">Amendments<span class="apple-converted-space"> </span><u><a href="http://docs.house.gov/Committee/Calendar/ByEvent.aspx?EventID=105173"><span style="color:#0062A0">here</span></a></u>.<o:p></o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><a href="https://energycommerce.house.gov/news-center/news/critical-response-we-need-115-leading-recovery-advocates-urge-support-opioid">This article</a> by the House Committee on Energy and Commerce stated on Wednesday that: “Support continues
to build for the draft legislative text circulated yesterday, which swiftly achieved the backing of 115 of the nation’s leading recovery advocacy groups. The Addiction Policy Forum spearheaded the effort urging support for the final package.”<o:p></o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal">Best,<o:p></o:p></p>
<p class="MsoNormal">Vivian<o:p></o:p></p>
<p class="MsoNormal"><b><span style="font-size:10.0pt;color:#333333">______________________________<br>
Vivian Fuhrman<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:10.0pt;color:#404040">Associate for Policy and Programs</span><span style="color:#404040"><o:p></o:p></span></p>
<p class="MsoNormal"><i><span style="font-size:10.0pt;color:#333333">Product Stewardship Institute, Inc.<br>
</span></i><span style="font-size:10.0pt;color:#333333">29 Stanhope St., 3rd Floor, Boston, MA 02116<br>
P: (617) 236-4771 F: (617) 236-4766<br>
</span><span style="font-size:10.0pt"><a href="http://www.productstewardship.us/" target="_blank"><span style="color:#333333">www.productstewardship.us</span></a><br>
<a href="mailto:vivian@productstewardship.us" target="_blank"><span style="color:#333333">vivian@productstewardship.us</span></a></span><o:p></o:p></p>
<p class="MsoNormal"><i><span style="font-size:10.0pt;color:#333333">The Product Stewardship Institute, Inc. is an equal opportunity provider and employer.<o:p></o:p></span></i></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>